Grants and Contributions:

Back to search
Title:
Establishing A Good Manufacturing Practices Protocol For Production Of “off The Shelf” Immunotherapies Derived From Cord Blood Stem Cells
Agreement Number:
1029082
Agreement Value:
$168,856.00
Agreement Date:
May 1, 2025 - Mar 30, 2026
Description:
Cancer is the leading cause of death in Canada, and while immunotherapy shows promise, it faces challenges such as high costs, long production times, and severe side effects. The Maganti laboratory at Canadian Blood Services has developed a small molecule cocktail to improve the production of "off-the-shelf" immune cells from cord blood stem cells. However, this technology needs optimization for clinical scale production of chimeric antigen receptor-expressing NK (CAR-NK) cells using good manufacturing practices (GMP). This proposal aims to create a GMP qualifying manufacturing protocol to produce CAR-NK cells (expressing a novel CD20 CAR) at clinical scale, making immunotherapy more accessible, affordable, and safer, ultimately improving cancer treatment in Canada.
Organization:
National Research Council Canada
Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:
Ottawa, Ontario, CA K1G 4J5
Reference Number:
172-2025-2026-Q1-1029082
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
870157641
Recipient Type:
Not-for-profit organization or charity
Recipient's Legal Name:
Canadian Blood Services
Federal Riding Name:
Ottawa South
Federal Riding Number:
35080
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:
541710